Taken together, these findings suggest that the acetate–FFAR2 molecular circuit protects against the development of NAFLD/NASH by directly regulating hepatic metabolism, rather than by ameliorating obesity. This evidence concerns the gene FFAR2 and metabolic dysfunction-associated steatotic liver disease.